P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Wiley
2022-06-01
|
| Edice: | HemaSphere |
| On-line přístup: | http://journals.lww.com/10.1097/01.HS9.0000846428.64094.91 |
| _version_ | 1827336324383768576 |
|---|---|
| author | F. B. Askeland E. Haukås T. S. Slørdahl D. Schjøll A. Lysen E. Hermansen F. Schjesvold |
| author_facet | F. B. Askeland E. Haukås T. S. Slørdahl D. Schjøll A. Lysen E. Hermansen F. Schjesvold |
| author_sort | F. B. Askeland |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:47Z |
| format | Article |
| id | doaj.art-3900a7e90b0a41c58ab033b51a8f11fe |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:47Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-3900a7e90b0a41c58ab033b51a8f11fe2024-03-02T06:40:49ZengWileyHemaSphere2572-92412022-06-01678078110.1097/01.HS9.0000846428.64094.91202206003-00780P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDYF. B. Askeland0E. Haukås1T. S. Slørdahl2D. Schjøll3A. Lysen4E. Hermansen5F. Schjesvold61 Oslo Myeloma Center, Department of Hematology3 Department of Cancer and Blood Diseases, Stavanger University Hospital, Stavanger4 Department of Hematology, St. Olavs Hospital, Trondheim, Norway5 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo1 Oslo Myeloma Center, Department of Hematology6 Department of Hematology, Zealand Iniversity Hospital, Roskilde, Denmark1 Oslo Myeloma Center, Department of Hematologyhttp://journals.lww.com/10.1097/01.HS9.0000846428.64094.91 |
| spellingShingle | F. B. Askeland E. Haukås T. S. Slørdahl D. Schjøll A. Lysen E. Hermansen F. Schjesvold P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY HemaSphere |
| title | P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY |
| title_full | P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY |
| title_fullStr | P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY |
| title_full_unstemmed | P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY |
| title_short | P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY |
| title_sort | p888 replacing steroids in transplant ineligible multiple myeloma the phase 2 isatuximab bortezomib lenalidomide dexamethasone rest study |
| url | http://journals.lww.com/10.1097/01.HS9.0000846428.64094.91 |
| work_keys_str_mv | AT fbaskeland p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy AT ehaukas p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy AT tsslørdahl p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy AT dschjøll p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy AT alysen p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy AT ehermansen p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy AT fschjesvold p888replacingsteroidsintransplantineligiblemultiplemyelomathephase2isatuximabbortezomiblenalidomidedexamethasonereststudy |